Medical Technology

@xconomy.com 3 years ago

Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Black Diamond Lines Up IPO as Lead Cancer Drug Nears Clinic

@xconomy.com 4 years ago

Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More

@xconomy.com 4 years ago

Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone

@xconomy.com 5 years ago

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

@xconomy.com 5 years ago

San Antonio Develops “Action Plan” to Draw Life Sciences Businesses

@xconomy.com 5 years ago

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues

@xconomy.com 5 years ago

With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care

@xconomy.com 5 years ago

IPO Wave Rolls On as Five Life Science Firms Haul in $651M

@xconomy.com 5 years ago

CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells

@xconomy.com 6 years ago

Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs